#Followers1 .followers-grid, #Followers1 .followers-count { display: none !important; }

Monday, 12 May 2025

Haemostasis: Balancing Bleeding and Clotting in the Human Body ๐Ÿฉธ

 Haemostasis is the body's finely tuned process of maintaining blood flow while preventing excessive bleeding or clot formation. It operates through a delicate equilibrium of pro-coagulant and anti-coagulant proteins, ensuring that blood remains fluid under normal conditions but can rapidly clot when injury occurs.

The Three Phases of Haemostasis

1️⃣ Vasoconstriction & Injury Response
  • When a blood vessel is injured, local vasoconstriction occurs to minimize blood loss.
  • Collagen and tissue factor are exposed, signaling platelets to respond.
2️⃣ Primary Haemostasis: Platelet Plug Formation
  • Platelets adhere to exposed von Willebrand factor (vWF), initiating adhesion.
  • Activated platelets release ADP and thromboxane A2, triggering further platelet aggregation.
  • Platelets form a temporary plug through fibrinogen bridges, stabilizing the site of injury.
  • This process kickstarts the coagulation cascade.
3️⃣ Secondary Haemostasis: Coagulation Cascade Activation
  • The intrinsic and extrinsic pathways lead to the activation of Factor X, initiating the common pathway.
  • Factor X converts prothrombin (Factor II) into thrombin (Factor IIa), a key enzyme in clot formation.
  • Thrombin transforms fibrinogen (Factor I) into insoluble fibrin, reinforcing the clot.
  • Factor XIII cross-links fibrin strands, stabilizing the clot further.

The Intrinsic vs. Extrinsic Pathways: How Does Clotting Begin?

๐Ÿฉธ Intrinsic Pathway: Triggered when Factor XII contacts negatively charged collagen on damaged endothelium. Platelets release Factor VIII, which combines with Factor IX, ultimately activating Factor X.

๐Ÿฉธ Extrinsic Pathway: Initiated when Factor VII exits circulation following injury. Tissue factor (Factor III) binds Factor VII, activating Factor X.

๐Ÿ”ฌ Key Test Indicators:

  • Prothrombin Time (PT) measures the extrinsic pathway.
  • Activated Partial Thromboplastin Time (aPTT) assesses intrinsic pathway function.
  • D-dimer levels indicate ongoing fibrinolysis, helping assess clot breakdown activity

Fibrinolysis: Clearing Clots Once Healing Begins

Once tissue repair is complete, plasminogen is converted into plasmin, degrading the fibrin clot into soluble fragments.

๐Ÿ’Š Tranexamic acid inhibits plasmin formation, reducing excessive bleeding in clinical settings.

D-dimers are protein fragments produced after fibrinolysis – can be used to screen for increased fibrinolytic activity


Clotting Regulators: Preventing Unchecked Thrombosis

Several proteins help regulate haemostasis, preventing excessive clot formation:
✅ Antithrombin – Inhibits thrombin and several clotting factors.
✅ Protein C & Protein S – Work together to degrade Factors Va and VIIIa, slowing clotting.
✅ Tissue Factor Pathway Inhibitor – Inhibits the TF-VIIa complex to prevent excessive Factor X activation.

๐Ÿ’ก Clinical Correlations: When Haemostasis Fails

๐Ÿ”ด Bleeding Disorders:
  • Von Willebrand Disease (VWD): Deficiency or dysfunction of vWF leads to prolonged bleeding, commonly affecting mucosal surfaces.
  • Haemophilia A & B: Factor VIII or IX deficiencies impair the intrinsic pathway, causing deep tissue and joint bleeding.
๐Ÿฉธ Clotting Disorders:
  • Factor V Leiden Mutation: A genetic predisposition to thrombosis due to resistance to Protein C regulation.
  • Antiphospholipid Syndrome: Autoimmune condition increasing thrombotic risk through abnormal antibody-mediated clot formation.


Assessing Bleeding & Clotting Disorders: Key Questions & Investigations

When evaluating a patient for a bleeding or clotting disorder, a structured approach is crucial. The history provides essential diagnostic clues, while laboratory investigations confirm the underlying pathology.

Key Questions for Bleeding Disorders
1️⃣ Is there evidence of a bleeding problem?
  • History of easy bruising, epistaxis, gum bleeding, or prolonged menstrual bleeding?
  • Excessive bleeding after surgery, trauma, or dental procedures?
2️⃣ What is the location of bleeding?
  • Mucosal bleeding (nose, gums, GI tract)? → Suggests platelet dysfunction or von Willebrand disease.
  • Joint or deep tissue bleeding? → Often seen in haemophilia or coagulation factor deficiencies.
3️⃣ What is the timing of bleeding relative to a haemostatic challenge?
  • Immediate bleeding post-injury → More likely platelet-related.
  • Delayed bleeding (hours to days) → Suggests coagulation factor deficiency (e.g., haemophilia).
4️⃣ Medication history?
  • Use of aspirin, NSAIDs, anticoagulants (warfarin, DOACs), or herbal supplements that affect haemostasis?
5️⃣ Family history of bleeding disorders?
  • Consider haemophilia, von Willebrand disease, or rare inherited platelet disorders.

Key Investigations for Bleeding Disorders

๐Ÿ”ฌ Basic Tests:
✅ Full Blood Count (FBC) → Assess platelets and haemoglobin.
✅ Peripheral Blood Film → Look for platelet abnormalities or microcytic anaemia (suggestive of chronic blood loss).
✅ Standard Coagulation Screen:
  • Activated Partial Thromboplastin Time (aPTT) → Tests intrinsic pathway (Factors VIII, IX, XI, XII).
  • Prothrombin Time (PT) → Tests extrinsic pathway (Factors VII, X, V, II, I).
  • Thrombin Time (TT) → Assesses fibrinogen function.
  • International Normalized Ratio (INR) → Evaluates warfarin therapy or liver dysfunction.
✅ Fibrinogen levels → Identifies fibrinogen deficiency or consumption (e.g., DIC).

๐Ÿ”ฌ Specialty Tests:
✅ Von Willebrand Factor Antigen & Activity Assays → Diagnose VWD.
✅ Platelet Function Assays (PFA-100) → Evaluate platelet dysfunction.
✅ Mixing Studies → Differentiate factor deficiencies from inhibitors (e.g., lupus anticoagulant).
✅ Thrombophilia Workup (if suspect hypercoagulability) → Includes Factor V Leiden, Protein C/S, Antithrombin, Lupus Anticoagulant.

Key Questions for Clotting Disorders

1️⃣ Is there evidence of a clotting problem?
  • History of deep vein thrombosis (DVT), pulmonary embolism (PE), or recurrent pregnancy loss?
  • Unexplained stroke, myocardial infarction, or organ ischemia at a young age?
2️⃣ What are the risk factors?
  • Immobility, malignancy, smoking, or estrogen exposure (OCP, pregnancy)?
  • Recent surgery, trauma, or prolonged hospitalization?
3️⃣ Family history of clotting disorders?
  • Any relatives with DVT, PE, Factor V Leiden mutation, or other thrombophilia?
4️⃣ Medication history?
  • Use of hormonal contraceptives, chemotherapy, or pro-thromb๐Ÿฉธ๐Ÿฉธ๐Ÿฉธ๐Ÿฉธtic medications?

Key Investigations for Clotting Disorders


๐Ÿ”ฌ Basic Tests:
✅ FBC (platelet count) → Elevated platelets may indicate essential thrombocythemia, while low platelets may suggest DIC.
✅ D-dimer → Elevated in active clot formation (DVT/PE screening, DIC assessment).
✅ Standard Coagulation Screen (PT, aPTT, TT, INR) → Helps assess clotting pathway abnormalities.

๐Ÿ”ฌ Thrombophilia Screen (if clinically indicated):
✅ Factor V Leiden mutation → Most common inherited thrombophilia.
✅ Prothrombin Gene Mutation 20210A → Increases thrombotic risk.
✅ Protein C, Protein S, and Antithrombin III levels → Deficiencies lead to increased clotting tendency.
✅ Lupus Anticoagulant & Anticardiolipin Antibodies → Diagnose antiphospholipid syndrome.
✅ Anti-beta 2 Glycoprotein I Antibodies → Supports APS diagnosis.


No comments:

Post a Comment

↑ Back to top